Kandice King, APRN
Nurse Practitioner · Westlake, LANPI 1629448154
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Novo Nordisk at 53.2% of the total. 2025 is the largest year on record at $262, more than ten times the $17 reported in 2021. That places this record below the midpoint for nurse practitioner clinicians in LA, where the typical reported total is $207.
Across 18 payments — averaging $16.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$156
- Amgen$28
- Exact Sciences$20
- Lilly USA, LLC$20
- AstraZeneca$18
- Axsome Therapeutics, Inc.$17
- plus $35 from 3 others
What the payments were for
- Food & beverage$294100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 9 | $156 |
| Amgen | 2 | $28 |
| Exact Sciences | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| AstraZeneca | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| BTG International Inc. | 1 | $4 |
How this compares
$294 in reported general payments places this provider in the 50th percentile of 969 nurse practitioner providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 34 | $334 |
| Azithromycin | 64 | $279 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $222 |
| Doxycycline Monohydrate | 20 | $164 |
| Mupirocin | 17 | $124 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 20 | $97 |
| Ciprofloxacin Hcl | 16 | $96 |
| Diclofenac Sodium | 11 | $59 |
| Cyclobenzaprine Hcl | 12 | $38 |
| Ibuprofen | 11 | $32 |
| Meloxicam | 11 | $17 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Westlake
- Karen DeshotelLafayette$264K
- Christopher ManuelKaplan$145K
- Tammy BennettShreveport$99K
- Jessica BordelonHammond$78K
- Matt LandryLafayette$50K
- Cynthia CobbLafayette$48K
- Ellen GentileWest Monroe$31K
- Reghan LittlepageAlexandria$24K
- April WoodrowOpelousas$24K
- Amanda EstapaHammond$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.